Bovine Mastitis Market Size, Share, Forecast 2025-2032|Top Companies Virbac, Forte Healthcare Inc., Immucell Corporation, Heilsaa, and HIPRA, Elanco

The global bovine mastitis market was valued at USD 2.45 billion in 2024 and is projected to reach USD 5.36 billion by 2032, expanding at a CAGR of 9.15% from 2025 to 2032. Market growth is primarily driven by the increasing prevalence of udder infections in dairy cattle and the rising awareness among farmers and livestock owners regarding timely diagnosis and treatment. As mastitis continues to be one of the most common and costly diseases affecting dairy production, the demand for effective therapeutic and preventive solutions is accelerating worldwide.

The COVID-19 pandemic had a noticeable impact on the bovine mastitis industry. Global lockdowns and supply chain disruptions restricted the availability of raw materials and veterinary pharmaceuticals, delaying treatment accessibility in several regions. Additionally, many farmers reduced or postponed routine veterinary check-ups due to mobility restrictions and concerns about infection, leading to delays in disease detection and management.

Key Points of Bovine Mastitis Market Covered:
 Market Revenue of Bovine Mastitis Market from 2021 to 2032.
 Market Size of Bovine Mastitis Market from 2021 to 2032.
 Market Forecast for Bovine Mastitis Market from 2025 to 2032.
 Regional Bovine Mastitis Market Share and Revenue from 2021 to 2032.
 Countries Level Market Share within Region from 2021 to 2032.
 Company Market Share analysis, competitive scenario, ranking and detailed company profiles.
 Market Drivers, Market Restraints, and detailed COVID-19 impact on Bovine Mastitis Market.

Request for a Free Sample page: https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

One of the key factors fueling the growth of the bovine mastitis market is the increasing global demand for dairy products. Rising population levels, coupled with higher disposable incomes, have boosted consumption of milk, cheese, yogurt, butter, and other dairy-based foods. This trend places dairy producers under growing pressure to deliver high-quality, safe, and consistent output to meet consumer expectations.

Because udder infections can significantly reduce both milk yield and quality, managing mastitis effectively has become a top priority for dairy farmers. As a result, there is a stronger focus on advanced treatment methods and preventive strategies to minimize losses associated with bovine mastitis. Investments in animal health solutions are rising as producers seek to protect herd productivity and secure reliable supply chains.

Download Free Sample Pages of Bovine Mastitis Market: https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

Global Bovine Mastitis Market Report Segmentation:

The report projects revenue growth across, global, regional, and country levels, offering a comprehensive analysis of the latest industry trends within each sub-segment from 2021 to 2032. For this study, Delta Minds Research has categories the Bovine Mastitis Market by Product, by Type, by Therapy, by Route of Administration, by End Use and by region. The Product is further segmented to Pharmaceuticals, Diagnostics. The Type is further segmented to Clinical Mastitis, Sub-Clinical Mastitis. The Therapy is further segmented to Dry Period, Lactating Period. The Route of Administration is further segmented to Intra-Mammary, Systemic. The End Use is further segmented to Veterinary Hospitals/Clinics, Others.

Product Analysis Insights

The bovine mastitis market is segmented into pharmaceuticals and diagnostics, with pharmaceuticals maintaining a clear lead in revenue share. In 2024, the pharmaceuticals segment accounted for over 61.20% of total market revenue, reflecting the widespread use of antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), and hormonal therapies for mastitis management. These treatments are essential for addressing both clinical and subclinical udder infections, thereby reducing inflammation and preventing complications that could lower milk productivity.

According to the Cornell University College of Veterinary Medicine, antibiotics remain the primary line of therapy for bovine mastitis, underlining their central role in disease management. The availability of a broad spectrum of pharmaceutical options and their proven effectiveness in treating infected cattle reinforce this segment's dominance in the global market.

The diagnostics segment is projected to expand at a CAGR of 9.21% between 2025 and 2032, driven by technological advancements and the presence of leading market players offering innovative solutions. Modern tools, such as VetMAX MastiType multiplex qPCR kits from Thermo Fisher Scientific Inc., enable veterinarians to detect mastitis pathogens, including Mycoplasma species, within the same day.
These rapid testing methods eliminate the need for traditional bacterial culture while delivering faster and more accurate results, allowing farmers and veterinarians to take timely action. The growing emphasis on early disease detection, herd productivity, and cost-effective treatment planning is expected to fuel further adoption of diagnostic solutions in the coming years.

Type Analysis Insights:

In 2024, clinical mastitis accounted for the largest share of the bovine mastitis market. Clinical mastitis is characterized by visible changes in milk composition, such as discoloration or fibrin clots, along with physical alterations in the udder, including swelling, heat, pain, and redness. These symptoms make the disease easier to detect, leading to high treatment adoption. Common therapies include antibiotics, anti-inflammatory medications, and supportive solutions, creating a significant market demand for clinical mastitis management.

Meanwhile, the subclinical mastitis segment is projected to expand at the fastest CAGR during the forecast period. Subclinical infections are more widespread but harder to detect, as they typically show no visible symptoms. Diagnosis often relies on screening tools such as somatic cell count (SCC) testing, which identifies inflammation at an early stage. Although less urgent than clinical cases, subclinical mastitis can result in chronic inflammation, reduced milk yield, and long-term economic losses, making preventive care and diagnostics increasingly vital.

Therapy Analysis Insights:

The dry period therapy segment dominated the market in 2024. During the cow's non-lactating stage, animals are highly vulnerable to subclinical infections, which can later develop into clinical mastitis during lactation. Preventive antibiotic administration during this phase has long been a standard practice. However, recent emphasis on antibiotic stewardship has accelerated the adoption of Selective Dry Cow Therapy (SDCT), where antibiotics are prescribed only for infected animals. This shift supports sustainable practices while ensuring disease prevention, driving growth in this segment.

The lactating period therapy segment is expected to record the fastest CAGR through 2032. Mastitis during lactation remains a common and recurring issue in dairy herds, requiring effective diagnostic, preventive, and treatment measures. The continued rise in udder infections among lactating cows is expected to increase the demand for advanced solutions such as rapid testing kits, targeted antibiotics, and supportive therapies, thereby fueling segment growth.

Route of Administration Analysis Insights:

The intra-mammary administration segment held the dominant share in 2024. This delivery route is favored for its ability to directly target the infected mammary gland, ensuring higher concentrations of medication at the site of infection. Such precision improves outcomes for bacterial infections, including Staphylococcus aureus and Escherichia coli, while minimizing systemic drug exposure. Reduced side effects and shorter milk withdrawal periods are particularly attractive benefits for dairy farmers seeking to maintain productivity.

This segment is also forecasted to expand at the fastest growth rate over the next decade, supported by the wide availability of intra-mammary therapeutic solutions. Companies such as Boehringer Ingelheim Animal Health offer well-established products like PolyMast, ToDAY, Dry-Clox, and Lockout, which provide effective intra-mammary treatment for mastitis.

Download free PDF on Bovine Mastitis Market @ https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

List of Key Players in Bovine Mastitis Market:

The top 10 key players covered and analyzed in detailed for Bovine Mastitis are Virbac, Forte Healthcare Inc., Immucell Corporation, Heilsaa, and HIPRA, Elanco, Ceva, Merck, Zoetis, Boehringer

Regional Analysis for Bovine Mastitis Market:

 North America (United States, Canada).
 Europe (UK, France, Italy, Spain, Russia, Denmark, Norway, Sweden, Rest of Europe)
 Asia Pacific (Japan, China, India, Australia, Thailand, South Korea, Rest of Asia Pacific)
 Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
 Middle East and Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East and Africa)

Download Free Sample Bovine Mastitis Market Overview: https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

Detailed Table of Content on Bovine Mastitis Market:

 Chapter 1: Global Bovine Mastitis Market Overview.
 Chapter 2: Market Dynamics.
 Chapter 3: Competitive Landscape.
 Chapter 4: North America Bovine Mastitis Market Revenue & Trends Analysis (2021-2032).
 Chapter 5: Europe Bovine Mastitis Market Revenue & Trends Analysis (2021-2032).
 Chapter 6: Asia Pacific Bovine Mastitis Market Revenue & Trends Analysis (2021-2032).
 Chapter 7: Latin America Bovine Mastitis Market Revenue & Trends Analysis (2021-2032).
 Chapter 8: Middle East and Africa Bovine Mastitis Market Revenue & Trends Analysis (2021-2032).
 Chapter 9: Appendix.

Download Full Report and Detailed Table of Content of this report @ https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

Frequently Asked Questions

Q1. How big is the Bovine Mastitis Market?
Answer: The global Bovine Mastitis Market was valued at approximately USD 2.45 Billion in 2024 and is projected to witness significant growth over the forecast period.

Q2. What is the Bovine Mastitis Market Growth
Answer: The Bovine Mastitis Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.15% from 2025 to 2032.

Q3: What is the market value of Bovine Mastitis Market in 2024?
Answer: In 2024, the global Bovine Mastitis Market was valued at approximately USD 2.45 Billion, reflecting a steady increase in demand from key regions such as North America, Asia Pacific, and Europe, Latin America, Middle East and Africa.

Q4: What is the forecasted market value of Bovine Mastitis Market in 2032?
Answer: By 2032, the global Bovine Mastitis Market is projected to reach USD 5.36 Billion, marking a strong upward trend fueled by technological advancements

Q5: What is the Base year considered in the Bovine Mastitis Market?
Answer: The base year considered for the Bovine Mastitis Market report is 2024, with the forecast period ranging from 2025 to 2032.

Q6: Which Region accounted for the largest Bovine Mastitis Market Share?
Answer: In 2024, North America held the largest share in the Bovine Mastitis Market

Q7: Who are the Top Key Players in Bovine Mastitis Market?
Answer: Some of the major players operating in the Bovine Mastitis Market include Virbac, Forte Healthcare Inc., Immucell Corporation, Heilsaa, and HIPRA, Elanco, Ceva, Merck, Zoetis, Boehringer who focus on innovation, product expansion, and strategic partnerships to gain a competitive edge.

Q8: What are the factors driving the Bovine Mastitis Market?
Answer: The growth of the Bovine Mastitis Market is primarily driven by increasing demand, ongoing technological advancements, expanding applications across industries, rising investments, and growing consumer awareness. Favorable government policies and global market expansion also contribute to sustained market development.

Q9: What are the restraining factors which will hinder the growth of Bovine Mastitis Market?
Answer: Key challenges affecting the growth of the Bovine Mastitis Market include high implementation costs, regulatory hurdles, limited awareness in developing regions, and market saturation in mature economies. Additionally, supply chain disruptions and fluctuating raw material prices may pose constraints.

Download Free Bovine Mastitis Market Report: https://deltamindsresearch.com/industries/healthcare-biotechnology/bovine-mastitis-market-size-share-forecast-report-2025-2032/

Name: Amol Thorat
Company: Delta Minds Research
Email: amol.thorat@deltamindsresearch.com
Web: https://deltamindsresearch.com

Delta Minds Research is a globally recognized market intelligence firm that delivers high-quality, data-driven insights to businesses across a variety of industries. With a mission to empower companies to make informed decisions, Delta Minds Research has become a trusted partner for decision-makers seeking in-depth, actionable market intelligence. Through a commitment to accuracy, reliability, and affordability, the firm provides reports that not only support strategic initiatives but also drive growth, enhance competitive advantage, and unlock new opportunities in a rapidly changing marketplace.

Delta Minds Research operates in a wide range of industries, providing deep insights and analysis to help companies navigate complex market environments. Our expertise spans technology, healthcare, finance, energy, manufacturing, logistics, e-commerce, and many other sectors. By focusing on both emerging and established markets, Delta Minds Research is able to offer a comprehensive understanding of industry-specific trends, challenges, and opportunities, making our reports indispensable for businesses striving to stay ahead of the competition.

This release was published on openPR.